Efficacy of Tranexamic Acid Versus Topical 4% Hydroquinone in Melasma

Comparison of Efficacy of Intralesional Tranexamic Acid Versus Topical 4% Hydroquinone in Treating Melasma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220709055422N1

Enrollment

290

Registered

2022-07-17

Start date

2018-10-16

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma .. L81.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM L81.1 became effective on October 1, 2021.This is the American ICD-10-CM version of L81.1 - other international

Interventions

Intervention 1: Intervention group: Patients received weekly intradermal injections of 0.5 ml Tranexamic acid in 0.5 ml normal saline (50 mg/ml) into the melasma lesion at 1 cm intervals using a steri

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients suffering from melasma

Exclusion criteria

Exclusion criteria: history of discoid lupus erythematosus pregnancy lactation anemia oral contraceptives or hormone replacement therapy

Design outcomes

Primary

Measure	Time frame
Efficacy was evaluated on the basis of fall in MASI score for Melasma from base line. Timepoint: Interventions were Offred for a period of 12 weeks. Follow up was done at 4 weekly intervals for 12 weeks. After 12 weeks final response was assessed. All patients were called for follow up and efficacy was evaluated on the basis of fall in MASI score from base line. Method of measurement: MASI score was measured by a trained physician on each visit.	—

Measure

Time frame

Efficacy was evaluated on the basis of fall in MASI score for Melasma from base line. Timepoint: Interventions were Offred for a period of 12 weeks. Follow up was done at 4 weekly intervals for 12 weeks. After 12 weeks final response was assessed. All patients were called for follow up and efficacy was evaluated on the basis of fall in MASI score from base line. Method of measurement: MASI score was measured by a trained physician on each visit.

—

Countries

Pakistan

Contacts

Public ContactDr Muhammad Rizwan

Pak-Emirates Military Hospital Rawalpindi

rizwan_rawalian2000@gmail.com+92 333 5373829

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026